Furthermore, in GC tissue samples, PD-L1 expression on tumor cells positively correlates with the presence of CTLs in the stroma and IFN-γ expression in the tumor, suggesting that PD-1/PD-L1 antagonists’ function better in GC patients whose TME contains a significant proportion of CTLs [99,100]. This evidence concerns the gene PDCD1 and neoplasm.